基因工程抗体及其发展前景.pptVIP

2021/3/14 * 小分子抗体 分子量小,穿透性强,抗原性弱,表达容易,易于进行基因工程改造,可用于医学影像学分析 需提高其小分子抗体的稳定性,使重轻链分子在表达后能进行充分的折叠;提高与抗原的结合能力以及表达系统的优化 胞内抗体、催化抗体:胞内抗体是指在细胞内表达,可以特异性结合细胞内蛋白靶点,从而起到调控细胞内信号转导途径,调节细胞代谢过程的小分子抗体。催化抗体又称抗体酶,是指具有蛋白酶催化活性的抗体。该技术在有机化学领域具有很好的应用前景。 2021/3/14 * 抗体药物 “生物导弹” 特异性好,疗效显著,靶点明确,机理清楚 抗体治疗作用的发挥主要依靠 （1）抗体与靶抗原的特异性结合 （2）利用抗体的识别特异性,发挥导向作用,将效应分子“运输”至特定区域发挥作用。 效应分子主要包括三类,即放射性核素（如I131）、化学药物（如氨甲喋呤）和植物、细菌毒素（如阿霉素、长春碱类衍生物）。另外,也有连接细胞因子、肽类分子的抗体治疗剂。 2021/3/14 * 抗体与抗原结合介导的应答 2021/3/14 * 抗体药发挥治疗作用的三种机制 2021/3/14 * return 2021/3/14 * Pharmacokinetics of intact antibodies versus fragments 2021/3/14 * Chemical structures of some advanced mAb-drug conjugates.  2021/3/14 * Fig. 2B. Schematic representation of the mechanism of antibody targeting specific cells against HIV-infected cells. Mechanisms of in vivo action: Fig2.B A general view of the conjugation of a bifunctional chelating agent to a monoclonal antibody. 2021/3/14 * Antibody engineering elements 2021/3/14 * 寄语 1。科学研究需要激情和热情。 2。学习是永无止境的。 3。敢于挑战和勇于创新。 热情,好学, 创新和享受过程,而不仅是结果. 谢 谢! * * * * Monoclonal antibodies were among the first biopharmaceuticals developed.1 As with antibodies produced naturally by the immune system against pathogens and toxins, monoclonal antibodies are highly specific for their target.2 Over the years, technology has advanced from monoclonal antibodies cloned from 100% mouse DNA to the development of fully human monoclonal antibodies with lower potential for immunogenicity.1-5 In the 1980s, Kohler and Milstein developed a method (“hybridoma technology”) for producing an unlimited supply of a single antibody with affinity and specificity for a defined target.2 The first therapeutic antibodies consisted of 100% mouse protein, but had limitations such as immunogenicity, short elimination half-life, and decreased treatment response due to development of human anti-murine antibodies or HAMAs.1,3-5 Efforts were undertaken to develop new types of monoclonal antibodies to address the limitations associated